2,760
Participants
Start Date
December 13, 2017
Primary Completion Date
April 30, 2025
Study Completion Date
August 31, 2025
Apixaban
Refer to Apixaban group
Rivaroxaban
Refer to Rivaroxaban group
The University of Sydney, Darlington
University of Calgary, Calgary
Alberta Health Sciences, Edmonton
St. Paul's Hospital, Vancouver
Hamilton General Hospital, Hamilton
Juravinski Hospital, Hamilton
St. Joseph's Healthcare Hamilton, Hamilton
Kingston General Hospital, Kingston
Hôpital Sacré-Coeur de Montréal, Montreal
St. Mary's Hospital, Montreal
CHU de Québec-Université Laval, Québec
University of Sherbrooke, Sherbrooke
The Royal College of Surgeons in Ireland/Mater Misericordiae University Hospital, Dublin
QEII Health Science Centre, Halifax
London Health Sciences Center, London
The Ottawa Hospital - General Campus, Ottawa
UHN - Toronto General Hospital, Toronto
Jewish General Hospital, Montreal
McGill University Health Center, Montreal
Lead Sponsor
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
NETWORK
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Ottawa Hospital Research Institute
OTHER